A5093861860- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Genomic variations and chromosomal abnormalities
- Congenital Anomalies and Fetal Surgery
- Blood disorders and treatments
- Pregnancy and Medication Impact
- Congenital heart defects research
- Electrolyte and hormonal disorders
- Transplantation: Methods and Outcomes
- Extracellular vesicles in disease
- MicroRNA in disease regulation
- Renal Diseases and Glomerulopathies
- Complement system in diseases
University of Padua
2024
Città della Speranza Foundation
2024
The early identification of a subclinical rejection (SCR) can improve the long-term outcome transplanted kidney through intensified immunosuppression. However, only approved diagnostic method is protocol biopsy, which remains an invasive and not without minor and/or major complications. biopsy defined as sampling allograft tissue at pre-established times even in absence impaired renal function; however, it does avoid histological damage. Therefore, discovery new possible biomarkers useful...
Complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are ultra-rare chronic kidney diseases with an overall poor prognosis, approximately 40-50% of patients progressing to failure within 10 years diagnosis. C3G is characterized by a high rate disease recurrence in the transplanted kidney. However, there lack published data on clinical outcomes pediatric population following transplantation.
The relatively rare proximal 17q12 microdeletion, including the deletion of HNF1B gene, is associated with renal cysts and diabetes syndrome (RCAD). This genomic rearrangement results in a wide range phenotypes, diabetes, which are consistent maturity-onset young type 5 (MODY5), Mullerian aplasia/dysgenesis, autism spectrum disorder schizophrenia, speech delay, learning difficulties, transient neonatal hypercalcemia, cholestasis. We describe girl microdeletion identified using CGH array...
Antibody-mediated rejection (AMR) is the leading cause of premature kidney transplant failure. The role alloantibodies against Human Leukocyte Antigens (HLA) has been a primary focus in AMR. More recently autoantibodies and angiotensin II receptor type 1 (AT1R) endothelin A (ETAR) have linked to poor allograft outcomes transplantation. Nevertheless, evidence supporting routine testing remains insufficient. ELISA for anti-AT1R anti-ETAR antibodies was performed pediatric renal cohort. We...